Cost of managing constipation among terminally ill cancer patients treated with transdermal fentanyl and 12 hour sustained-release morphine in Canada

Journal of Medical Economics

Volumn 2, Issue 1-4, 1999, Pages 15-32

  Flynn, T N ^a   Guest, J F ^a  

^a CATALYST Health Economics Consultants   (United Kingdom)

Author keywords

cancer; constipation; costs; fentanyl; morphine; opioid; palliative care; resource use

Indexed keywords

FENTANYL; MORPHINE SULFATE;

ARTICLE; CANADA; CANCER; CANCER PATIENT; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HEALTH CARE COST; HOSPITAL ADMISSION; HUMAN; ORAL DRUG ADMINISTRATION; PALLIATIVE THERAPY; RANDOMIZED CONTROLLED TRIAL; SUSTAINED RELEASE FORMULATION; TERMINAL DISEASE; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0033053715     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/199902015032     Document Type: Article

References (20)

1. Bruera E, Suarez-Almazor M, Velasco A et al. The assessment of constipation in terminal cancer patients admitted to a palliative care unit: a retrospective review. J Pain Symp Manag 1994;9(8):515-519.
2. White T. Dealing with constipation. Nursing Times 1995;91(14):57-60.
3. Burke AB. The management of constipation in end-stage disease. Australian Family Physician 1994;23(7):1248-1253.
4. Ahmedzai S & Brooks D. Transdermal fentanyl versus sustained-release morphine in cancer pain: preference, efficacy, and quality of life. J Pain Symp Manag 1997;13(5):254-261. (Pubitemid 27240678)
5. Ahmedzai S, Allan E, Fallon M et al. Transdermal fentanyl in cancer pain. J Drug Dev 1994;6:93-97. (Pubitemid 24082103)
6. Zech F F J, Grond S U A, Lynch et al. Transdermal fentanyl and initial dosefinding with patient controlled analgesia in cancer pain - a pilot study with 20 terminally ill cancer patients. Pain 1992;50:293-301.
7. Jeal W & Benfield P. Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 1997;53(1):109-138. (Pubitemid 27042235)
8. Korte W, de Stoutz N & Morant R. Day-today titration to initiate transdermal fentanyl in patients with cancer pain: short-and long-term experiences in a prospective study of 39 patients. J Pain Symp Manag 1996;11:139-146 (Pubitemid 26090589)
9. Donner B, Zenz M, Strumpf M & Raber M. Long-term treatment of cancer pain with transdermal fentanyl. J Pain Symp Manag 1998;15:168-175. (Pubitemid 28169139)
10. Slover R. Transdermal fentanyl: Clinical trial at the University of Colorado Health Sciences Center. J Pain Symp Manag 1992;7:S4547.
11. Megens A A H P, Artois K, Vermeire J et al. Comparison of the analgesic and intestinal effect of fentanyl and morphine in rats. J Pain Symp Manag 1998;15:253-257.
12. Ontario Ministry of Health; Schedule of Benefits. February 1998.
13. Ontario Ministry of Health; Drug Benefit Formulary/Comparative Drug Index. August 1997.
14. Jacobs P, Hall EM & Bachynsky J. An Alberta Standard Cost List for Health Economic Evaluations. 1996. In Press.
15. Twycross R. Update on analgesics. In: Kaye, P (ed), Tutorials in Palliative Medicine, Northampton, EPL Publications, 1997:94-131.
16. Nugent M, Davis C, Brooks D et al. Longterm follow-up of patients receiving transdermal fentanyl (Durogesic). 1997; Abstract P-020 & poster presented at the 6th Congress of the European Association for Palliative Care, London, September, 1997.
17. Bloor K, Leese B & Maynard A. The costs of managing severe cancer pain and potential savings from transdermal administration. Eur J Cancer 1994;30A(4):463-468. (Pubitemid 24171952)
18. Duggan AK. The cost of constipation in morphine patients and the economic possibilities with tramadol. B J Med Econ 1995;9:21-29.
19. Guest JF, Munro V & Cookson R. Comparison of the cost of managing constipation in cancer patients receiving oral morphine or transdermal fentanyl. European Journal of Cancer 1997;33(Suppl 9):S19.
20. Fifield M. Relieving constipation and pain in the terminally ill. Am J Nursing 1991;91:18-19.